Aris Miningの空売り状況は、投資家がAris Miningの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Aris Mining (AMEX:ARMN) 株価情報, 空売り情報

Aris Mining

Aris Mining Corp is engaged in the acquisition, exploration, development and operation of gold properties in Colombia, Guyana and Canada. It owns and operates its Segovia Operations, Soto Norte Project and Marmato Mine in Colombia, Toroparu Project in Guyana and the Juby Project in Ontario, Canada. The company generates revenue from the sale of gold and silver.

Aris Mining Corp

WIIM

ING Group shares are trading lower after the company reported a year-over-year decline in Q4 financial results.

News

Guidance

Under Armour Raises FY25 Adj. EPS Guidance From $0.24-$0.27 To $0.28-$0.30; Raised Adj. Operating Income Guidance From $165M-$185M To $185M-$195M.

Dividends

Restaurants

General

Yum! Brands' Board Of Directors Approved A 6% Increase In The Company's Quarterly Dividend From $0.67 To $0.71 Per Share And Be Distributed March 7, 2025 To Shareholders Of Record At The Close Of Business On February 21, 2025

Barclays analyst Benjamin Budish maintains Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) with a Overweight and lowers the price target from $224 to $217.

Price Target

Analyst Ratings

ARES

Barclays Maintains Overweight on Ares Management, Lowers Price Target to $217

CONMED Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) posted better-than-expected earnings for its fourth quarter, but issued FY25 <a href="https://www.benzinga.com/quote/CNMD/earnings">earnings and revenue guidance below estimates.</a>
Conmed reported quarterly earnings of $1.34 per share which beat the analyst consensus estimate of $1.20 per share. The company reported quarterly sales of $345.94 million which beat the analyst consensus estimate of $341.01 million.
&#8220;2024 was a year of solid sales and earnings growth but was also challenging as we navigated persistent supply challenges for parts of our business. I am pleased with our progress in the fourth quarter, particularly with respect to our improved profitability,&#8221; commented Patrick J. Beyer, CONMED&#8217;s President and Chief Executive Officer. &#8220;In 2025, we are laser focused on improving our operations and strengthening our foundation for future above-market revenue and profitability growth.&#8221;
Conmed said it sees FY2025 adjusted EPS of $4.25-4.40, versus market estimates of $4.74. The company expects sales of $1.344 billion-1.372 billion, versus projections of $1.40 billion.
Conmed shares gained 1.5% to close at $74.00 on Wednesday.
These analysts made changes to their price targets on Conmed following earnings announcement.
<ul>
<li>JP Morgan analyst Robbie Marcus downgraded Conmed from Overweight to Neutral and lowered the price target from $85 to $70.</li>
<li>Needham analyst Mike Matson maintained Conmed with a Buy and lowered the price target from $97 to $91..</li>
</ul>
Considering buying CNMD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="595" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06065648/image-55-1024x595.png" alt="" class="wp-image-769181" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06065648/image-55-1024x595.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06065648/image-55-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06065648/image-55-768x446.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06065648/image-55.png 1105w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43493237/jim-cramer-this-health-care-stock-is-a-winner-buy-bitcoin-instead-of-coinbase">Jim Cramer: This Health Care Stock Is A &#8216;Winner,&#8217; Buy Bitcoin Instead Of Coinbase</a></li>
</ul>

Earnings

Markets

Trading Ideas

CNMD

These Analysts Slash Their Forecasts On Conmed After Q4 Results

B of A Securities analyst Allen Lutz maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Neutral and raises the price target from $10.5 to $11.5.

TDOC

B of A Securities Maintains Neutral on Teladoc Health, Raises Price Target to $11.5

Net sales for the 4-week fiscal month ended February 1, 2025 decreased 18.0 percent to $59.5 million from net sales of $72.6 million for the prior year 5-week fiscal month ended February 3, 2024.

Buckle January Comparable Store Net Sales Increase 4.4%

Liquidity Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDT#NASDAQ">LQDT</a>) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.22 by 27.27 percent. This is a 100 percent increase over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $122.331 million which beat the analyst consensus estimate of $105.356 million by 16.11 percent. This is a 71.51 percent increase over sales of $71.325 million the same period last year.

Earnings Beats

LQDT

Liquidity Services Q1 2025 Adj. EPS $0.28 Beats $0.22 Estimate, Sales $122.331M Beat $105.356M Estimate

Biotech

Health Care

ETON

The FDA Has Extended The Prescription Drug User Fee Act (PDUFA) Goal Date For Eton Pharmaceuticals' New Drug Application For ET-400. The New PDUFA Goal Date Is May 28

2025 Full-Year Financial Outlook Summary The company expects net sales growth of at least 2%, driven primarily by net price realization. Reported earnings per share is expected to be down in the high-40% range as higher commodity costs, rebased incentive compensation, and a higher economic tax rate are expected to more than offset price realization, productivity and cost savings programs.&nbsp; The company projects adjusted earnings per share to be down in the mid-30% range when excluding one-time costs associated with cost savings initiatives and acquisition integration activities.&nbsp; The gap between the reported and adjusted earnings per share growth outlooks primarily reflects a large derivative mark-to-market gain recorded in reported earnings per share in 2024.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">2025 Full-Year Outlook</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Total Company</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net sales growth4</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">At least 2%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Reported earnings per share growth</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Down high-40% range</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted earnings per share growth</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Down mid-30% range</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">4 The impact of the Sour Strips acquisition is anticipated to be an approximate 30 basis point benefit to net sales growth for the full-year 2025. Additionally, the impact of foreign currency exchange rates is anticipated to be an approximate 30 basis point headwind to net sales growth for the full-year 2025.</td>
</tr>
</tbody>
</table>
</figure>
The company also expects:
<ul>
<li>A reported and adjusted effective tax rate in the range of approximately 14% to 15%;</li>
<li>Other expense, which primarily reflects the write-down of equity investments that qualify for a tax credit, of approximately $170 million to $180 million;</li>
<li>Interest expense of approximately $190 million to $195 million, reflecting a higher interest rate environment;</li>
<li>Capital expenditures of approximately $425 million to $450 million, as capital spending as a percentage of sales returns to historical levels; and</li>
<li>Advancing Agility &amp; Automation Initiative savings of approximately $125 million.</li>
</ul>

Hershey Sees FY2025 Adj EPS $6.00-$6.18 vs $7.36 Est; Sees Sales $11.426B vs $11.40B Est

Under Armour Q3 EPS $0.00, Sales $1.401B Beat $1.341B Estimate

Needham analyst James Ricchiuti maintains Coherent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) with a Buy and raises the price target from $120 to $125.

COHR

Needham Maintains Buy on Coherent, Raises Price Target to $125

"Global raw material volumes remain robust and stronger fat prices in the first quarter of 2025 should provide lift as pending tariffs and the Clean Fuel Production Credit provide greater certainty to the value of domestic feedstocks," the company said.

Darling Ingredients Expects 2025 To Be Stronger Than 2024; Expects $1.25B - $1.30B Combined Adjusted EBITDA

nVent Electric Sees FY25 Adjusted EPS Of $2.98-$3.08 Vs. $2.98 Estimate; Projects Organic Sales Growth Of 4%-6%

Barclays analyst Adam Seiden maintains AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) with a Overweight and raises the price target from $105 to $120.

Barclays Maintains Overweight on AECOM, Raises Price Target to $120

The earnings results for A P Moller Maersk (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AMKBY#OTC">AMKBY</a>) for Q4 were made public on Thursday, February 6, 2025 at 04:00 AM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
A P Moller Maersk beat estimated earnings by 56.00000000000001%, reporting an EPS of $0.67 versus an estimate of $0.43.
Revenue was up $2.85 billion from the same period last year.
<h3>Previous Earnings Records</h3>
The company missed on EPS by $0.02 in the previous quarter, leading to a 4.0% increase share price change the next day.

To track all earnings releases for A P Moller Maersk <a href="https://www.benzinga.com/quote/AMKBY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMKBY

Earnings Summary: A P Moller Maersk Q4

Affiliated Managers Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMG#NYSE">AMG</a>) reported quarterly earnings of $6.53 per share which beat the analyst consensus estimate of $6.02 by 8.47 percent. This is a 4.81 percent decrease over earnings of $6.86 per share from the same period last year. The company reported quarterly sales of $524.20 million which missed the analyst consensus estimate of $530.55 million by 1.20 percent. This is a 4.28 percent increase over sales of $502.70 million the same period last year.

Earnings Misses

Affiliated Managers Group Q4 Adj EPS $6.53 Beats $6.02 Estimate, Sales $524.20M Miss $530.55M Estimate

APTV

Aptiv Expects FY25 Net Sales Of $19.6B - $20.4B (Est $19.96B), Adj EPS Of $7.00 - $7.60 (Est $6.92)

Benchmark analyst Cody Acree reiterates Skyworks Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) from Hold to Hold.

Reiteration

SWKS

Benchmark Reiterates Hold on Skyworks Solutionsto Hold

Guidance for 2025
The following guidance assumes foreign exchange rates effective as of December&nbsp;31, 2024, for the full year. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases and dividends.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="5" rowspan="1">(Dollars in billions, except per share data)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Results</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">2025 Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2024</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Low</td>
<td colspan="1" rowspan="1">High</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Labcorp Enterprise (1)(2)</td>
<td colspan="1" rowspan="1">$13.01</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">6.7&nbsp;%</td>
<td colspan="1" rowspan="1">8.0&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Diagnostics Laboratories (3)</td>
<td colspan="1" rowspan="1">$10.14</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">6.5&nbsp;%</td>
<td colspan="1" rowspan="1">7.7&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Biopharma Laboratory Services (4)</td>
<td colspan="1" rowspan="1">$2.92</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">3.0&nbsp;%</td>
<td colspan="1" rowspan="1">5.0&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS</td>
<td colspan="1" rowspan="1">$14.57</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$15.60</td>
<td colspan="1" rowspan="1">$16.40</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow</td>
<td colspan="1" rowspan="1">$1.10</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$1.10</td>
<td colspan="1" rowspan="1">$1.25</td>
</tr>
</tbody>
</table>
</figure>

Laboratory Corporation Of America Holdings

Labcorp Expects 2025 Sales Of $13.88B-$14.05B Versus Consensus Of $13.79B, and Adjusted EPS Of $15.60-$16.40 Versus Consensus Of $16.02

Aris Mining Corporation 2024 Q3 - Results - Earnings Call Presentation

Aris Mining Corporation (ARMN) Q3 2024 Earnings Call Transcript

BMO Capital analyst Brian Quast lowered the firm's price target on Aris Mining (ARMN) to C$8.50 from C$9 and keeps an Outperform rating on the shar...

Aris Mining price target lowered to C$8.50 from C$9 at BMO Capital

Brian Quast, an analyst from BMO Capital, maintained the Buy rating on Aris Mining (ARIS – Research Report). The associated price target was lowere...

Aris Mining: Strong Operational Efficiency and Strategic Financial Moves Justify Buy Rating

National Bank lowered the firm's price target on Aris Mining (ARMN) to C$8.50 from C$9 and keeps an Outperform rating on the shares. Published firs...

Aris Mining price target lowered to C$8.50 from C$9 at National Bank

Aris Mining (TSE:ARIS) has released an update. Aris Mining is navigating a proposed Colombian Ministry of Environment resolution that temporarily h...

Aris Mining Adapts to Environmental Resolution

Gold Mining Stocks: Winners And Losers At The Start Of 2025

Top 5 Mining Stocks To Watch In 2025: No.2 - Aris Mining

Aris Mining ( ($TSE:ARIS) ) has shared an announcement. Aris Mining Corporation reported achieving its 2024 gold production guidance with a total o...

Aris Mining Achieves 2024 Production Goals and Sets Ambitious 2025 Outlook

BMO Capital lowered the firm's price target on Aris Mining (ARMN) to C$8 from C$9.50 and keeps an Outperform rating on the shares. Published first ...

Aris Mining price target lowered to C$8 from C$9.50 at BMO Capital

ARMN

CLGDF

GOLD

PAAS

RGLD

SAND

SILV

SSRM

TPRXF

Press Releases

ARIS MINING REPORTS H1 2024 NET EARNINGS OF $5.0M, ADJUSTED EARNINGS OF $18.1M ($0.12/SHARE) AND EBITDA OF $53.2M WHILE SEGOVIA EXPANSION AND CONSTRUCTION OF MARMATO LOWER MINE REMAIN ON TRACK

Comments

Aris Mining

空売り

Aris Mining (AMEX:ARMN) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル